Waystar Considers Sale Amidst Falling Valuation, Sources Reveal

Waystar, a prominent player in healthcare software known for its payment management solutions, is reportedly exploring strategic options, including a possible sale. This move comes just two years after the company's public listing in New York. Seven sources familiar with the situation disclosed that the Lehi, Utah, and Louisville, Kentucky-based firm has engaged investment bank Evercore to oversee the process.

According to two of these sources, who requested anonymity due to the confidential nature of the discussions, the exploration is still in its early stages. They cautioned that the plans are not finalized, and a sale may not ultimately occur. Both Waystar and Evercore declined to comment on the matter.

Market Challenges and Valuation Concerns

Waystar's current market valuation stands at approximately $4.8 billion, following a 24% drop in its share price this year. This decline is part of a broader downturn affecting the software sector. Analysts suggest that an auction could serve as a barometer for investor interest in software companies amidst ongoing market volatility.

The company has positioned itself as a technology-driven entity, focusing on automating administrative tasks in healthcare. This strategic choice aimed to capitalize on the higher valuations typically associated with tech firms, rather than being perceived as a service-heavy business. Initially, this strategy paid off, with share prices soaring from $20 to a peak of $45 in 2025. However, concerns over potential disruptions from advancements in artificial intelligence have since put pressure on the stock, according to a Morgan Stanley report from July.

Background and Ownership

Waystar emerged from the 2017 merger of Zirmed and Navicure, both of which specialized in healthcare revenue management. Its major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, who collectively took the company public in 2024. EQT holds the largest share at 13%, followed by CPPIB with 10%, and BlackRock Institutional Trust Company with 8%, as reported by LSEG data.

As the company navigates these strategic considerations, its major investors have largely remained silent. EQT and BlackRock declined to comment, while CPPIB did not respond to requests for comment.

Potential Implications

The outcome of Waystar's strategic review could have significant implications for the healthcare software sector, particularly in light of the current economic climate. A successful sale could signal renewed investor confidence in software companies, while a decision against selling might indicate a need to reassess market strategies and investor relations.

As the situation unfolds, stakeholders and market analysts will be closely watching for any developments that could impact the valuation and future direction of Waystar and similar companies in the industry.